QuidelOrtho Reports Third Quarter 2026 Financial Results
― Growth in Labs and Immunohematology Outside of China Highlights Underlying Business Strength ― ― New Cost Transformation and Enterprise…
Category
285 releases
― Growth in Labs and Immunohematology Outside of China Highlights Underlying Business Strength ― ― New Cost Transformation and Enterprise…
Beats revenue and profitability expectations
Third quarter 2026 net revenue of $353 million
Net Income increases 55% and Adjusted EBITDA increases 12% year-over-year
Added approximately 8,500 net new Locations in third quarter
Third Quarter Highlights Total revenues of $437.9 million in Q3 2026 compared to $411.8 million in Q2 2026 Net income of $27.7 million, or $0.93 per…
Announced positive topline induction data for SPY003 from Part A of the Phase 2 SKYLINE trial (“SKYLINE”), completing proof-of-concept for all three…
•AVLAYAH® (tividenofusp alfa-eknm) net product revenue accelerated to $17.8 million in its second full commercial quarter
Corvex, Inc. (Nasdaq: MOVE), an engineering-led AI computing platform specializing in GPU-accelerated infrastructure for AI workloads, today…
Solstice Advanced Materials (NASDAQ: SOLS), today announced that its Board of Directors has declared a regular quarterly dividend payment of seven…
Net Asset Value of $12.64 Per Share as of September 30, 2026
•Delivered total revenues in Q3 2026 of approximately $3.66 billion, exceeding guidance of $3.3 billion while growing 58.5%, the highest…